floridaretinainstitute.com

Surgery is a medical procedure that involves physically altering body tissue to diagnose, treat, or prevent a condition. Preparation depends on whether the procedure is planned or emergency, and on the type of surgery — for example, joint replacement requires different prep than hernia repair. At a specialty hospital such as Kansas Surgery & Recovery Center (KSRC), a physician-owned facility in Kansas focused on orthopedic surgery, preparation typically includes a pre-op evaluation, instructions on fasting and medication, and arrangements for recovery support.

Types of Surgery

Surgeries are commonly grouped by urgency and by the body system involved.

By urgency:

• Elective surgery — scheduled in advance because it is necessary but not time-critical. Total knee, hip, and shoulder replacements are typical examples.
• Emergency surgery — performed immediately to address a life- or limb-threatening condition.

By specialty or approach:

• Orthopedic surgery — focuses on bones, joints, and connective tissue. KSRC lists total joint surgery for knee, hip, and shoulder.
• Robotic-assisted surgery — uses a robotic system controlled by the surgeon to improve precision. KSRC names the DaVinci system for hernia and gallbladder surgery, and the Rosa Knee and Mako Knee systems for partial and total knee replacement, plus total hip procedures.
• Breast care surgery — also listed among KSRC's services.

How to Prepare for Surgery

Preparation generally follows the same broad steps whether you are having a joint replacement or another planned procedure.

1. Complete a pre-operative evaluation. Your surgeon or hospital will assess your overall health, review medications, and may order blood tests or imaging. KSRC provides new patient information to guide this stage.
2. Follow fasting instructions. You will typically be told not to eat or drink for a set period before surgery. Exact timing comes from your care team.
3. Review medications and supplements. Some drugs — including blood thinners — may need to be paused. Only your prescribing clinician should make that call.
4. Arrange transportation and recovery support. You will not be able to drive yourself home, and you may need help for several days.
5. Plan for accommodations if traveling. KSRC lists accommodations among its patient resources, which is useful if you are coming from outside the immediate area.
6. Understand the financial side. KSRC offers a price transparency page, a self-pay option, financial planning resources, and online payment. Reviewing these before your date helps avoid surprises.

What Recovery Looks Like

Recovery varies by procedure, but joint replacement patients often begin guided movement soon after surgery and follow a structured rehabilitation plan. KSRC describes itself as a recovery center and ranks highly for joint replacement surgery by HealthGrades, an independent health care rating company. That ranking is one signal to weigh when choosing where to have surgery — along with the surgeon's experience, the facility's procedure volume, and whether the equipment and approach match your needs.

Choosing a Surgical Facility

When comparing options, use the same criteria across providers:

KSRC states it is the state's leading orthopedic surgery specialty hospital and is physician-owned and operated. For questions, its main number is (316) 634-0090, and it offers a contact form and patient portal access.

Diagnosis of a bone or soft tissue tumor is a structured process that moves from symptoms and imaging to a tissue sample examined under a microscope. The goal is to determine whether a lesion is benign or malignant, identify its exact type and grade, and stage how far it has spread. Because musculoskeletal tumors are rare and varied, this process is best carried out by a specialized multidisciplinary sarcoma team, as emphasized by the European Musculo-Skeletal Oncology Society (EMSOS), whose stated aims include advancing the science and practice of the diagnosis and treatment of bone and soft tissue tumours.

Why the Diagnostic Process Matters

An accurate diagnosis is the foundation of treatment planning. Benign and malignant lesions can look similar on imaging, and different tumor types respond to very different treatments. A confirmed diagnosis tells the team:

• Whether the lesion is benign, locally aggressive, or malignant
• The specific tumor type (for example, among the many bone and soft tissue tumour entities)
• The grade, which reflects how aggressive the tumor is likely to be
• The stage, meaning whether the disease is localized or has spread

Each of these answers changes what happens next, from simple observation to surgery, chemotherapy, radiotherapy, or a combination.

Step 1: Clinical Assessment

The process usually begins with symptoms. Common reasons a patient seeks care include:

• A persistent or enlarging lump in an arm or leg
• Pain, especially pain that wakes the patient at night or persists at rest
• Swelling or reduced function in a limb
• An incidental finding on an X-ray taken for another reason

The clinician takes a history and performs a physical examination, noting the size, location, consistency, and mobility of any mass, as well as any neurological or vascular symptoms. These findings guide which imaging is requested first.

Step 2: Imaging

Imaging narrows the possibilities and maps the lesion before any tissue is taken.

X-ray

Often the first study for a suspected bone lesion. It shows the location of the abnormality within the bone, the pattern of bone destruction or formation, and features such as periosteal reaction that can suggest whether a process is benign or aggressive.

MRI

Magnetic resonance imaging is central for both bone and soft tissue tumors. It defines the extent of the lesion within the bone and its relationship to surrounding muscles, nerves, and vessels, and it helps plan a biopsy and later surgery.

CT

Computed tomography is useful for assessing cortical bone detail, for certain tumor types, and for staging the chest to check for lung spread, which is a relevant consideration in several musculoskeletal malignancies.

Additional imaging

Bone scans or PET-based imaging may be used to look for other sites of disease. The choice depends on the suspected diagnosis and the staging questions that need answering.

Imaging can strongly suggest a diagnosis, but it cannot confirm the tumor type on its own. That requires tissue.

Step 3: Biopsy

Biopsy obtains a tissue sample for examination by a pathologist and is the step that confirms whether a tumor is benign or malignant and what type it is.

Key points about biopsy in musculoskeletal oncology:

• Planning matters. The biopsy tract is placed so that it can be removed later during definitive surgery, because tumor cells can seed along the tract.
• The right technique is chosen. Options include core needle biopsy, incisional biopsy (removing a piece of the tumor), and excisional biopsy (removing the whole lesion). The choice depends on the lesion's size, location, and suspected type.
• Specialist pathologists are important. Musculoskeletal tumors are rare, and interpretation benefits from a pathologist experienced in bone and soft tissue pathology, sometimes with molecular or genetic testing to refine the diagnosis.

A biopsy performed without proper planning can compromise later treatment, which is one reason referral to a specialized center is recommended before the biopsy is done.

Step 4: Staging and Multidisciplinary Review

Once the diagnosis is confirmed, staging determines how far the disease has spread. This typically includes imaging of the chest and may include other studies depending on the tumor type.

The findings are then reviewed by a multidisciplinary team, which may include orthopedic oncologists, radiologists, pathologists, medical and radiation oncologists, and specialist nurses. This team combines the clinical, imaging, and pathology information to agree on a diagnosis and a treatment plan.

Why Specialized Teams Are Recommended

EMSOS describes its aims as advancing the science and practice of diagnosing and treating bone and soft tissue tumours, promoting basic and clinical research, and disseminating knowledge to provide a common high standard of musculo-skeletal oncology. This reflects a widely recognized principle in the field: because these tumors are rare and their management is complex, outcomes tend to be better when diagnosis and treatment are coordinated by an experienced sarcoma team.

Practical reasons include:

• Correct biopsy planning and technique
• Access to specialist pathology and molecular testing
• Consistent staging and multidisciplinary decision-making
• Treatment plans matched to the specific tumor type and stage

Common Questions

Can imaging alone diagnose a tumor? No. Imaging can suggest whether a lesion is benign or malignant and can guide biopsy, but a tissue sample is needed to confirm the diagnosis.

Does every lump need a biopsy? No. Some lesions have characteristic imaging features that allow observation or a clear benign diagnosis. The decision is made case by case by the treating team.

Why does the biopsy tract matter? Because tumor cells can spread along the tract, it is placed so it can be removed with the tumor during surgery.

What if the diagnosis is unclear after the first biopsy? Additional sampling, specialized pathology review, or molecular testing may be needed. This is one reason specialist centers are recommended.

Bottom Line

Diagnosing a bone or soft tissue tumor combines clinical assessment, imaging (X-ray, MRI, CT, and sometimes other studies), and a carefully planned biopsy interpreted by an experienced pathologist, followed by staging and multidisciplinary review. The process is designed to answer three questions: is it benign or malignant, what type and grade is it, and how far has it spread. Because each answer shapes treatment, having the diagnosis carried out by a specialized musculoskeletal oncology team is a key step toward the best possible outcome.

Treatment for bone and soft tissue tumours is planned around the specific tumour type, its grade and stage, and where it sits in the body. Most patients are treated by a multidisciplinary team at a specialist sarcoma centre, and the core options are surgery, chemotherapy, radiotherapy, and newer systemic or targeted therapies — often used in combination rather than alone. The sections below explain what each option does, how the sequence is decided, and what to expect during and after treatment.

The main treatment options

Surgery

Surgery is the mainstay of treatment for most bone and soft tissue tumours, and for many patients it is the only treatment needed. The goal is usually wide local excision: removing the tumour together with a margin of normal tissue around it, so that no tumour cells are left behind.

• Limb-sparing surgery removes the tumour while preserving the affected arm or leg. It is possible for many patients and is generally preferred when a safe margin can be achieved.
• Amputation is reserved for tumours where limb-sparing surgery cannot remove the tumour safely, or where the limb would not function afterwards.
• Reconstruction may follow removal of bone: options include metal prostheses, bone grafts, or other implants. The choice depends on the tumour's location, the patient's age, and how much bone was removed.

Chemotherapy

Chemotherapy uses drugs that travel through the bloodstream to kill tumour cells. In musculo-skeletal oncology it is used mainly for:

• Certain bone tumours, such as osteosarcoma and Ewing sarcoma, where it is a standard part of treatment.
• Some high-grade soft tissue sarcomas, particularly those at higher risk of spreading.
• Advanced or metastatic disease, to control tumour growth.

Chemotherapy is usually given as a series of cycles over several months, with rest periods in between.

Radiotherapy

Radiotherapy uses high-energy radiation to damage tumour cells. It is used more often for soft tissue sarcomas than for bone tumours, and can be given:

• Before surgery to shrink a tumour and make it easier to remove.
• After surgery when the margin is close or uncertain, to reduce the risk of local recurrence.
• As the main treatment when surgery is not possible or would cause unacceptable damage.
• For symptom relief in advanced disease.

Targeted and other systemic therapies

Beyond conventional chemotherapy, treatment may include drugs that act on specific molecular features of a tumour, or other systemic agents. Whether these are appropriate depends on the tumour's subtype and biology, and they are typically considered within specialist or trial settings.

How a treatment plan is decided

No single factor determines treatment. The team weighs several things together:

This is why treatment for the same named tumour can differ between two patients.

The role of the multidisciplinary team and specialist centres

A multidisciplinary team (MDT) brings together surgeons, medical and radiation oncologists, radiologists, pathologists, and specialist nurses to agree on a plan. Because these tumours are rare and their treatment is complex, guidance consistently points to management in specialist sarcoma centres, where teams see enough cases to make reliable judgements about margins, reconstruction, and systemic therapy.

The European Musculo-Skeletal Oncology Society (EMSOS) exists to advance the science and practice of diagnosing and treating bone and soft tissue tumours and to promote a common high standard of musculo-skeletal oncology across Europe — a reflection of how central specialist, team-based care is to this field.

Typical treatment sequences

Treatment is often described by where it sits relative to surgery:

• Neoadjuvant therapy — chemotherapy or radiotherapy given before surgery. It may shrink the tumour, make surgery easier, and in some tumours allows the response to treatment to be assessed.
• Adjuvant therapy — chemotherapy or radiotherapy given after surgery to reduce the risk of the tumour returning or spreading.
• Definitive or palliative treatment — when surgery is not the main approach, systemic therapy or radiotherapy may be used to control the disease or relieve symptoms.

Not every patient needs every step. Some are treated with surgery alone; others receive several treatments in sequence.

What to expect during and after treatment

• During treatment, expect regular imaging and clinical reviews to check how the tumour is responding and to catch complications early. Side effects depend on the treatment type and are managed by the care team.
• After treatment, follow-up usually continues for several years, with imaging and clinic visits at intervals. Follow-up looks for recurrence, spread, and late effects of treatment.
• Rehabilitation is often a major part of recovery, especially after limb-sparing surgery or amputation. Physiotherapy and, where needed, prosthetics or occupational therapy help restore function.

Questions to ask your care team

• What type and grade is my tumour, and what stage is it?
• Is surgery possible, and can it be limb-sparing?
• Do I need chemotherapy or radiotherapy, and if so, before or after surgery?
• What are the expected benefits and risks of each option?
• Is my case being discussed by a multidisciplinary team, and is it being managed at a specialist sarcoma centre?
• What follow-up and rehabilitation will I need?

The answers to these questions are what turn a general description of treatment into a plan for a specific patient.

Brazil ranks second in the IPIP.NET country-level table for both allocated ASNs (9,157) and announced ASNs (8,783), behind only the United States. The same row shows 77,606,656 IPv4 addresses and 31,373,490,721,038 IPv6 /64 blocks. If you are reading that row to judge how large, how concentrated, or how IPv6-ready Brazil's internet is, the four numbers answer different questions and should not be mixed.

What the Brazil row actually contains

The IPIP.NET table "Autonomous Systems and IP Address Allocations by Country / Region" lists, for each country or region:

• Allocated ASNs — autonomous system numbers assigned to that country/region in the registry records.
• Announced ASNs — ASNs actually visible in BGP announcements.
• ASN IPv4 Number — the count of IPv4 addresses associated with those ASNs.
• ASN IPv6 Number (/64) — the count of IPv6 address space expressed in /64 units.

For Brazil the values are:

Allocated vs. announced ASNs: what the gap means

Brazil's gap is 374 ASNs (9,157 − 8,783), or about 4.1% of allocated numbers. That is small. It means the overwhelming majority of ASNs assigned to Brazil are actually in use and visible in routing — not dormant allocations sitting in a registry.

For comparison, using the same table:

A large gap usually points to one of a few things: historical allocations that were never deployed, numbers held by organizations that stopped announcing, or registry assignments that never reached the routing table. Brazil's low gap suggests its ASN space is comparatively "live." India's high gap suggests a large share of allocated ASNs are not currently announced.

This is a routing-activity signal, not a measure of network quality or market maturity.

IPv4 addresses relative to ASN count

Brazil has 77,606,656 IPv4 addresses spread across roughly 8,783 announced ASNs — about 8,836 IPv4 addresses per announced ASN on average. That average is a rough density indicator, not a per-network figure; a handful of large carriers hold most of the space.

Two cautions when reading this number:

• The table reports addresses associated with ASNs attributed to Brazil, which is not the same as addresses geographically located in Brazil. A Brazilian-registered ASN can announce address space used elsewhere, and foreign ASNs can announce space used inside Brazil.
• IPv4 exhaustion means the number reflects historical allocation, not current demand. A country's IPv4 count says more about when it received space than about how much it needs now.

Why the IPv6 number looks enormous

The IPv6 figure — 31,373,490,721,038 — is counted in /64 blocks, not addresses. A single /64 contains 2^64 addresses, so the unit is deliberately coarse. The number is large because IPv6 space is allocated in vastly bigger chunks than IPv4.

Do not compare the IPv4 count (77,606,656) directly against the IPv6 count (31,373,490,721,038) and conclude Brazil has hundreds of thousands of times more IPv6 than IPv4. The units differ. The IPv6 column tells you how much /64-sized space is associated with Brazilian ASNs; the IPv4 column tells you how many individual IPv4 addresses. They are not the same kind of quantity.

What the IPv6 column is useful for is relative comparison between countries in the same table, since every row uses the same /64 unit.

Comparing Brazil with the United States and China

Using the same four columns:

Reading across:

• The United States leads on every column, with roughly 3.5× Brazil's allocated ASNs and about 19× its IPv4 addresses.
• Brazil has more allocated and announced ASNs than China, but far fewer IPv4 addresses (77.6M vs. 356.4M) and far less IPv6 /64 space.
• China has fewer ASNs but much larger address blocks per ASN, consistent with a more concentrated carrier structure.

So ASN count and address count measure different things: ASN count reflects how many distinct routing entities exist, while address count reflects how much space is held. A country can rank high on one and lower on the other, and Brazil is an example of that.

Common misreadings to avoid

• Treating ASN count as network size. Many small ASNs can outnumber a few large ones while holding less address space.
• Treating the IPv4 count as population-adjusted. The table gives absolute counts only; without population data you cannot derive per-capita figures from it.
• Comparing IPv4 and IPv6 columns directly. Different units, as explained above.
• Assuming country attribution equals geography. ASN-to-country mapping is registry-based and does not guarantee where traffic or infrastructure physically sits.
• Reading the gap as a quality score. A small allocated-to-announced gap shows routing activity, not performance, coverage, or reliability.

How to use the Brazil row in practice

If you need a quick, defensible statement about Brazil's internet from this table, the safe ones are:

• Brazil has the second-highest allocated and announced ASN counts in the table, after the United States.
• Its allocated-to-announced gap is small relative to peers like the United States and India, indicating most allocated ASNs are announced.
• Its IPv4 holdings are far smaller than China's despite having more ASNs, and its IPv6 /64 space is likewise smaller than China's.

Anything beyond that — market concentration, per-capita availability, IPv6 adoption rate — requires additional data the table does not provide.